Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2024 | TGFβi NKs with naxitamab and gemcitabine for GD2+ breast cancer

Margaret Gatti-Mays • 12 Dec 2024
SABCS 2024
Breast Cancer Antibodies Gemcitabine Naxitamab

Margaret Gatti-Mays, MD MPH, Ohio State University, Columbus, OH, introduces a Phase Ib/II trial (NCT06026657), which investigated the efficacy of ex vivo expanded allogenic universal donor TGFβi natural killer (NK) cells with gemcitabine chemotherapy and naxitamab, an anti-GD2 antibody, in patients with metastatic HER2-, GD2-expressing breast cancer. Naxitamab was employed to increase antigen presentation and the TGFβi NK cells enhanced the activity of chemotherapy with gemcitabine. This interview took place at 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Margaret Gatti-Mays

Strategies to overcome barriers in cancer vaccine efficacy
1:32
Strategies to overcome barriers in cancer vaccine efficacy
Margaret Gatti-Mays • 1 Jun 2025
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
1:28
Phase I trial of a therapeutic vaccine with checkpoint inhibitors for FLC
Margaret Gatti-Mays • 1 Jun 2025
SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC
2:04
SYNC-T therapy: in situ personalized cancer vaccination with intratumoral immunotherapy in mCRPC
Margaret Gatti-Mays • 1 Jun 2025
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer
1:40
Phase I study of B440, a WT1 cancer vaccine, in patients with metastatic urothelial cancer
Margaret Gatti-Mays • 1 Jun 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals